Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: Results of a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; De Botton, S.; Stein, E. M.; Roboz, G. J.; Mims, A. S.; Pollyea, D. A.; Swords, R. T.; Altman, J. K.; Collins, R. H.; Mannis, G. N.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Enasidenib (AG-221), a selective oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning is associated with favorable outcomes in mixed phenotype acute leukemia
    Journal Article

    Getta, B. M.; Roshal, M.; Zheng, J.; Park, J. H.; Stein, E. M.; Levine, R.; Papadopoulos, E. B.; Jakubowski, A. A.; Kernan, N. A.; Steinherz, P.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients
    Meeting Abstract

    Bixby, D.; Vigil, C. E.; Jurcic, J.; Cook, R.; Sekeres, M. A.; Rizzieri, D.; Cortes, J.; Redner, R.; Steensma, D.; Roboz, G.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
    Journal Article

    Amatangelo, M. D.; Quek, L.; Shih, A.; Stein, E. M.; Roshal, M.; David, M. D.; Marteyn, B.; Farnoud, N. R.; de Botton, S.; Bernard, O. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Journal Article

    Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Deangelo, D. J.; Levine, R. L.; Flinn, I. W.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Minimal residual disease in acute myeloid leukemia: Prognostication and pitfalls
    Journal Article

    Stein, E. M.
    Journal of Oncology Practice (2017)

    Fulltext@MSK | Save
  • Real-world treatment patterns and costs in medicare beneficiaries newly diagnosed with acute myeloid leukemia
    Meeting Abstract

    Stein, E. M.; Latremouille-Viau, D.; Guerin, A.; Shi, S.; Gagnon-Sanschagrin, P.; Briggs, O.; Bonifacio, G.; Joseph, G.
    Value in Health (2017)

    Fulltext@MSK | Save
  • Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
    Meeting Abstract

    Stein, E. M.; Yang, M.; Gao, W.; Galebach, P.; Xiang, C. Q.; Bhattacharyya, S.; Bonifacio, G.; Joseph, G. J.
    Value in Health (2017)

    Fulltext@MSK | Save
  • Patients with acute myeloid leukemia who have mutations in IDH1 or IDH2 respond well to induction chemotherapy with "7+3" despite the presence of complex karyotype or FLT3-ITD
    Meeting Abstract

    Gupta, D. M.; Devlin, D. S.; Tallman, D. M.; Stein, D. E.
    Haematologica (2017)

    Fulltext@MSK | Save